Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

ENT And Allergy Initiates A 'First Of Its Kind' Self-Insured Medical Malpractice Program
ENT and Allergy Associates, LLP (ENTA), is pleased to announce the formation of OASIS (i.e., Otolaryngology, Allergy Specialty Insurance Services), a separate company that will be a vehicle to provide Otolaryngology and Allergy Specific medical malpractice coverage. OASIS, which will be domiciled in the State of Vermont, is the first RRG to provide medical malpractice coverage exclusively to ENT physicians and Allergists. ENTA decided to embark on this path as a means of stabilizing its malpractice premiums in the face of mounting deficits among the State"s largest carriers and the failure of the legislature to pass any meaningful tort reform. These factors will most likely result in substantial premium increases well into the future. In addition, ENTA, now a 96 physician practice, will be able to focus on controlling the risks unique to its specialty to ensure patient safety and physician compliance with its risk management policies.
generic viagra online
Preseason Shoulder Strength May Determine Injury Severity For Baseball Pitchers
Athletic injuries can derail any player"s ability to compete, but for a baseball pitcher his shoulder strength and control is critical. A new study to be presented at the American Orthopaedic Society for Sports Medicine"s (AOSSM) Annual Meeting in Keystone, Colorado, suggests that testing a pitcher"s shoulder strength through a series of exercises during the preseason may help create a focused strength training program to prevent serious injury during the season.
News of the day
Oklahoma State Department Of Health Announces Results Of Triathlon Illness Investigation
The Oklahoma State Department of Health (OSDH) announced today that an investigation of gastrointestinal illness reported in a recent Oklahoma City triathlon was related to exposure to water during swimming practice sessions or during the swim portion of the event.
Sexual Health

Synergy Pharmaceuticals To Present Phase I Volunteer Study On SP-304 Investigational Drug To Treat GastroIntestinal Disorders At Upcoming Conference

Synergy Pharmaceuticals, Inc. (OTC BB: SGYP.OB SGY PNews), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that clinical data from the Phase I healthy volunteer study of SP-304, a new member of a class of investigational drugs for the treatment of irritable bowel syndrome with constipation (IBS-C), and chronic idiopathic constipation (CIC), will be presented at the Digestive Disease Week (DDW) annual meeting to be held in Chicago, IL from May 30 through June 4, 2009. The poster presentation entitled: "A Randomized, Double-blind, Placebo-Controlled, Single-, Ascending-, Oral-Dose Safety, Tolerability and Pharmacokinetic Study of SP-304 in Healthy Adult Human Male and Female Volunteers" by Kunwar Shailubhai, Ph.D., William A. Gerson, D.O., Craig Talluto, Ph.D. and G.S. Jacob, Ph.D. will be on Wednesday, June 3 from 8:00 am to 5:00 pm in the South Hall (McCormick Place). About SP-304 SP-304 is a member of a new class of non-systemic drugs for treatment of chronic constipation (CC), irritable bowel syndrome with constipation (IBS-C) and other GI diseases. SP-304 is a synthetic analog of uroguanylin, a natriuretic hormone that regulates ion and fluid transport in the GI tract. Orally administered SP-304 binds to and activates guanylate cyclase C (GC-C) expressed on epithelial cells lining the GI mucosa, resulting in activation of the cystic fibrosis transmembrane conductance regulator (CFTR), and leading to augmented flow of chloride and water into the lumen of the gut, facilitating bowel movement. In animal models, oral administration of SP-304 promotes intestinal secretion as well as ameliorating gastrointestinal inflammation. About Irritable Bowel Syndrome Up to one sixth of adults experience inflammatory bowel syndrome (IBS), a condition marked by disturbed bowel function and abdominal pain. IBS patients can have three different sets of symptoms; diarrhea-predominant (IBS-D), constipation-predominant (IBS-C) and mixed or alternating disorder (IBS-M). The split in prevalence between the forms is about 1/3rd each. In addition, most patients suffering from the mixed form of IBS (IBS-M) are believed to mainly have constipation. An estimated 10 million people in the US and an additional 10 million people in the EU suffer from IBS-C. IBS (all forms) accounts for 12% of adult visits to primary care physicians in the US. About Chronic Constipation Chronic constipation is a very common gastrointestinal disorder. Up to 26 million Americans suffer from the disorder, and of this population about 5 million have a severe condition necessitating relief. The prevalence of the disorder is similar in other developed countries. Patients with chronic constipation often experience hard stools, straining during bowel movements and not enough bowel movements during the week. People with chronic constipation can experience serious discomfort which adversely affects their ability to work and their quality of life. Synergy Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009